A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

NCT06521931 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopenia

Interventions

DRUG: PN20

Sponsor

Chongqing Peg-Bio Biopharm Co., Ltd.